SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 7, 2019--
Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public
offering of 6,325,000 shares of common stock, including 825,000 shares
sold upon full exercise of the underwriters’ option to purchase
additional shares, at a price to the public of $23.25 per share. The net
proceeds to Veracyte from the offering were approximately $137.9
million, after deducting underwriting discounts and commissions and
estimated offering expenses.
Morgan Stanley & Co. LLC and SVB Leerink LLC acted as lead book-running
managers for the offering. William Blair acted as a book-running manager
and BTIG and Janney Montgomery Scott acted as co-managers.
The public offering was made pursuant to an effective shelf registration
statement filed with the Securities and Exchange Commission on May 2,
2019. This offering was made solely by means of a prospectus supplement
and accompanying prospectus relating to and describing the terms of the
offering, copies of which may be obtained by contacting Morgan Stanley &
Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor,
New York, New York 10014; or SVB Leerink LLC, Attention: Syndicate
Department, One Federal Street, 37th Floor, Boston, Massachusetts 01220,
by email at firstname.lastname@example.org
or by telephone at (800) 808-7525, ext. 6132.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or other
Veracyte, Afirma, Percepta, Envisia, Know by Design, the Veracyte logo
and the Afirma logo are trademarks of Veracyte, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190507005968/en/
Source: Veracyte, Inc.
Investor and Media Contact:
Angie McCabe, (650) 243-6371